IRWD Chief Commercial Officer automatic sale of 6,016 shares reported

Rhea-AI Filing Summary

Ironwood Pharmaceuticals Inc. (IRWD) reported an insider transaction by its Chief Commercial Officer. On 11/17/2025, the officer sold 6,016 shares of Class A common stock at $3.32 per share. According to the disclosure, this sale was made automatically to cover tax withholding obligations arising from the vesting of restricted stock units and was not a discretionary trade. After this transaction, the officer beneficially owned 235,264 shares of Ironwood common stock.

Insider Trade Summary

Net Seller: 6,016 shares ($19,973)

Net Sell 1 txn

Insider Gaskins Tammi L

Role Chief Commercial Officer

Sold 6,016 shs ($20K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	6,016	$3.32	$20K

Holdings After Transaction: Class A Common Stock — 235,264 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gaskins Tammi L

(Last) (First) (Middle)

C/O IRONWOOD PHARMACEUTICALS, INC.

100 SUMMER STREET, SUITE 2300

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IRONWOOD PHARMACEUTICALS INC [ IRWD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	11/17/2025		S(1)		6,016	D	$3.32	235,264	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the Reporting Person.

	/s/ Amir Vitale, Attorney-in-Fact	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did IRWD report in this Form 4?

Ironwood Pharmaceuticals reported that its Chief Commercial Officer sold 6,016 shares of Class A common stock on 11/17/2025 at a price of $3.32 per share.

Why did the Ironwood (IRWD) officer sell 6,016 shares?

The filing states the 6,016-share sale was required to cover tax withholding obligations related to the vesting of restricted stock units and occurred automatically as a sell-to-cover transaction.

Was the IRWD insider sale a discretionary trade?

No. The explanation notes the sale does not represent a discretionary trade by the reporting person and occurred automatically to satisfy tax withholding obligations.

How many IRWD shares does the officer own after this transaction?

Following the reported transaction, the Chief Commercial Officer beneficially owned 235,264 shares of Ironwood Pharmaceuticals Class A common stock in direct ownership.

What type of security was involved in the IRWD Form 4 transaction?

The transaction involved Class A common stock of Ironwood Pharmaceuticals Inc. (ticker IRWD).

What is the relationship of the reporting person to Ironwood Pharmaceuticals (IRWD)?

The reporting person is an officer of Ironwood Pharmaceuticals, serving as the company’s Chief Commercial Officer.